FullHope Biomedical Co (ROCO:7773) Net Margin %: -68.72% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7773 FullHope Biomedical Co Ltd ROCO:7773
22 GF Score
Price NT$36.15
! 2 Warning Signs
View Full Analysis

What is FullHope Biomedical Co Net Margin %?

FullHope Biomedical Co ROCO:7773 +2.84% 22 Net Margin % is -68.72% as of Jun. 2026. GuruFocus rates ROCO:7773 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, FullHope Biomedical Co ranks better than 51.06% on this metric.

Net margin is calculated as Net Income divided by its Revenue. FullHope Biomedical Co's Net Income for the six months ended in Jun. 2026 was NT$-14.70 Mil. FullHope Biomedical Co's Revenue for the six months ended in Jun. 2026 was NT$21.39 Mil. Therefore, FullHope Biomedical Co's net margin for the quarter that ended in Jun. 2026 was -68.72%.

The historical rank and industry rank for FullHope Biomedical Co's Net Margin % or its related term are showing as below:

ROCO:7773' s Net Margin % Range Over the Past 10 Years
Min: -305.76   Med: -220.78   Max: -69.25
Current: -69.25

ROCO:7773's Net Margin % is ranked better than
51.06% of 942 companies
in the Biotechnology industry
Industry Median: -77.59 vs ROCO:7773: -69.25

FullHope Biomedical Co  (ROCO:7773) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

FullHope Biomedical Co Net Margin % Related Terms

FullHope Biomedical Co Net Margin % Historical Data

* Premium members only.

The historical data trend for FullHope Biomedical Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

FullHope Biomedical Co Net Margin % Chart

FullHope Biomedical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
0.00 -305.76 -168.90 -272.65 -89.33

FullHope Biomedical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Net Margin % Get a 7-Day Free Trial Premium Member Only -308.35 -251.24 -117.10 -69.69 -68.72

ROCO:7773 vs VRTX, REGN, RVMD: Net Margin % Comparison

For the Biotechnology subindustry, FullHope Biomedical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FullHope Biomedical Co Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FullHope Biomedical Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where FullHope Biomedical Co's Net Margin % falls into.


ROCO:7773
22GF Score
FullHope Biomedical Co Ltd ROCO:7773
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

FullHope Biomedical Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

FullHope Biomedical Co's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-38.946/43.6
=-89.33 %

FullHope Biomedical Co's Net Margin for the quarter that ended in Jun. 2026 is calculated as

Net Margin=Net Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-14.697/21.386
=-68.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -68.72% mean?
FullHope Biomedical Co (ROCO:7773) has a Net Margin % of -68.72% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on FullHope Biomedical Co and its competitors. According to the industry distribution chart, FullHope Biomedical Co ranks #461 out of 942 companies in the Biotechnology industry, placing it in the top 48.9%.
Is FullHope Biomedical Co's Net Margin % too high?
FullHope Biomedical Co's current Net Margin % is -68.72%. Based on the distribution chart, FullHope Biomedical Co ranks #461 out of 942 companies in the Biotechnology industry, which is above the industry midpoint. Overall, FullHope Biomedical Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does FullHope Biomedical Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, FullHope Biomedical Co ranks #461 out of 942 companies for Net Margin %. This puts FullHope Biomedical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on FullHope Biomedical Co and its competitors. FullHope Biomedical Co's current Net Margin % is -68.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is FullHope Biomedical Co stock overvalued right now?
FullHope Biomedical Co (ROCO:7773) has a current Net Margin % of -68.72%. The current Net Margin % is -68.72%. FullHope Biomedical Co's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For FullHope Biomedical Co (ROCO:7773), the current Net Margin % is -68.72% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

FullHope Biomedical Co Business Description

Address Lane 609, Sector. 5, Chongxin Road, 10th Floor, No. 10, Sanchong District, New Taipei City, TWN
FullHope Biomedical Co Ltd focuses on immune system-related services and innovative R&D. It establishes cell-based immunotherapies for cancers and autoimmune disorders. Its services are, Immunoprofiling, Circulating Tumor Cells Testing, Regulation of Cell Therapy, Contracting Immune Cell Manufacturing, Immune Cell Bank, Contract Research Organization, and Endotoxin and Mycoplasma Detection Service.
22GF Score

Get the complete analysis for ROCO:7773

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$36.15
Price